These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35986031)

  • 41. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
    Hu X; Yang Y; Gong D
    Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurofilament light chain as a biomarker of meningoencephalitis of unknown etiology in dogs.
    Yun T; Koo Y; Chae Y; Lee D; Kim H; Kim S; Chang D; Na KJ; Yang MP; Kang BT
    J Vet Intern Med; 2021 Jul; 35(4):1865-1872. PubMed ID: 34114244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ
    Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms.
    Edén A; Grahn A; Bremell D; Aghvanyan A; Bathala P; Fuchs D; Gostner J; Hagberg L; Kanberg N; Kanjananimmanont S; Lindh M; Misaghian S; Nilsson S; Schöll M; Sigal G; Stentoft E; Studahl M; Yilmaz A; Wang M; Stengelin M; Zetterberg H; Gisslén M
    JAMA Netw Open; 2022 May; 5(5):e2213253. PubMed ID: 35604688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease.
    Kanata E; Golanska E; Villar-Piqué A; Karsanidou A; Dafou D; Xanthopoulos K; Schmitz M; Ferrer I; Karch A; Sikorska B; Liberski PP; Sklaviadis T; Zerr I; Llorens F
    J Clin Neurosci; 2019 Feb; 60():124-127. PubMed ID: 30309804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurofilament light chain: a promising diagnostic biomarker for functional motor disorders.
    Dinoto A; Marcuzzo E; Chiodega V; Dall'Ora F; Mariotto S; Tinazzi M
    J Neurol; 2023 Mar; 270(3):1754-1758. PubMed ID: 36370187
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neurofilament Light Chain Levels in Frontotemporal Dementia and Progressive Supranuclear Palsy: A Systematic Review.
    Bendstrup N; Hejl AM; Salvesen L
    J Alzheimers Dis; 2022; 87(1):131-140. PubMed ID: 35275542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease.
    Abu-Rumeileh S; Baiardi S; Ladogana A; Zenesini C; Bartoletti-Stella A; Poleggi A; Mammana A; Polischi B; Pocchiari M; Capellari S; Parchi P
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1181-1188. PubMed ID: 32928934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis.
    Gaetani L; Eusebi P; Mancini A; Gentili L; Borrelli A; Parnetti L; Calabresi P; Sarchielli P; Blennow K; Zetterberg H; Di Filippo M
    Mult Scler Relat Disord; 2019 Oct; 35():228-232. PubMed ID: 31404762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).
    Nicoletti TF; Rossi S; Vita MG; Perna A; Guerrera G; Lino F; Iacovelli C; Di Natale D; Modoni A; Battistini L; Silvestri G
    J Neurol; 2022 Sep; 269(9):5085-5092. PubMed ID: 35575811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia.
    Kessler C; Serna-Higuita LM; Rattay TW; Maetzler W; Wurster I; Hayer S; Wilke C; Hengel H; Reichbauer J; Armbruster M; Schöls L; Martus P; Schüle R
    Ann Clin Transl Neurol; 2021 May; 8(5):1122-1131. PubMed ID: 33819388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
    Poesen K; De Schaepdryver M; Stubendorff B; Gille B; Muckova P; Wendler S; Prell T; Ringer TM; Rhode H; Stevens O; Claeys KG; Couwelier G; D'Hondt A; Lamaire N; Tilkin P; Van Reijen D; Gourmaud S; Fedtke N; Heiling B; Rumpel M; Rödiger A; Gunkel A; Witte OW; Paquet C; Vandenberghe R; Grosskreutz J; Van Damme P
    Neurology; 2017 Jun; 88(24):2302-2309. PubMed ID: 28500227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
    Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
    Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
    Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
    Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.